Applications of TALENs and CRISPR/Cas9 in Human Cells and Their Potentials for Gene Therapy

被引:33
|
作者
Niu, Jingwen [1 ,2 ]
Zhang, Bin [1 ,2 ]
Chen, Hu [1 ,2 ]
机构
[1] Acad Mil Med Sci, Dept Hematopoiet Stem Cell Transplantat, Affiliated Hosp, Beijing 100071, Peoples R China
[2] Acad Mil Med Sci, Cell & Gene Therapy Ctr, Beijing 100071, Peoples R China
关键词
TALENs; CRISPR/Cas9; Genome editing; Gene therapy; CCR5; NUCLEASES; CAS9; SPECIFICITY; EFFICIENT; TRANSCRIPTION; NICKING; STEM; GENERATION; RESISTANCE; CONVERSION;
D O I
10.1007/s12033-014-9771-z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The newly developed TALENs and emerging CRISPR/Cas9 have spurred interests in the field of genome engineering because of their ease of customization and high-efficient site-specific cleavages. Although these novel technologies have been successfully used in many types of cells, it is of great importance to apply them in human-derived cells to further observe and evaluate their clinical potentials in gene therapy. Here, we review the working mechanism of TALEN and CRISPR/Cas9, their effectiveness and specificity in human cells, and current methods to enhance efficiency and reduce off-target effects. Besides, CCR5 gene was chosen as a target example to illustrate their clinical potentials. Finally, some questions are raised for future research and for researchers to consider when making a proper choice bases on different purposes.
引用
收藏
页码:681 / 688
页数:8
相关论文
共 50 条
  • [41] Somatic Gene Therapy of Mucopolysaccharidosis with CRISPR/Cas9 Genome Editing
    Kao, Winston W. Y.
    Ferreira, Tarsis
    Dong, Fei
    Hu, Yueh-Chiang
    Call, Mindy Kay
    Coulson-Thomas, Vivien Jane
    Zhang, Jianhua
    Rice, Taylor
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [42] Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy
    Wang, Yanan
    Jiang, Haibin
    Li, Mopu
    Xu, Zidi
    Xu, Hang
    Chen, Yuetong
    Chen, Kepei
    Zheng, Weihong
    Lin, Wei
    Liu, Zhiming
    Lin, Zhenlang
    Zhang, Min
    GENE, 2024, 927
  • [43] CRISPR/Cas9 technology as a potent molecular tool for gene therapy
    Karimian, Ansar
    Azizian, Khalil
    Parsian, Hadi
    Rafieian, Sona
    Shafiei-Irannejad, Vahid
    Kheyrollah, Maryam
    Yousefi, Mehdi
    Majidinia, Maryam
    Yousefi, Bahman
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (08) : 12267 - 12277
  • [44] Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure
    Soriano, Vicente
    AIDS REVIEWS, 2017, 19 (03) : 173 - 174
  • [45] CRISPR/Cas9 for cancer research and therapy
    Zhan, Tianzuo
    Rindtorff, Niklas
    Betge, Johannes
    Ebert, Matthias P.
    Boutros, Michael
    SEMINARS IN CANCER BIOLOGY, 2019, 55 : 106 - 119
  • [46] CRISPR/Cas9
    杨丽
    中南医学科学杂志, 2016, 44 (05) : 585 - 585
  • [47] CRISPR/Cas9
    Mizuno, Naoaki
    Mizutani, Eiji
    Sato, Hideyuki
    Kasai, Mariko
    Nakauchi, Hiromitsu
    Yamaguchi, Tomoyuki
    BIO-PROTOCOL, 2019, 9 (13):
  • [48] CRISPR/Cas9 gene-editing strategies in cardiovascular cells
    Vermersch, Eva
    Jouve, Charlene
    Hulot, Jean-Sebastien
    CARDIOVASCULAR RESEARCH, 2020, 116 (05) : 894 - 907
  • [49] Knockin (KI) in rat zygotes with TALENs and CRISPR/Cas9 systems as protein forms
    Menoret, Severine
    de Cian, Anne
    Tesson, Laurent
    Remy, Severine
    Fontaniere, Sandra
    Thinard, Reynald
    Usal, Claire
    Savignard, Chloe
    Fraichard, Alexandre
    Nguyen, Tuan H.
    Concordet, Jean-Paul
    Giovannangeli, Carine
    Anegon, Ignacio
    TRANSGENIC RESEARCH, 2014, 23 (05) : 883 - 883
  • [50] Application of CRISPR/Cas9 gene editing to primary T cells
    Li, Xi
    Tang, Wanbing
    Zhou, Chenjie
    Yang, Yulin
    Peng, Zhengang
    Zhou, Wenrong
    Ji, Qunsheng
    Cang, Yong
    CANCER RESEARCH, 2018, 78 (13)